MADRID, Aug. 31, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously published in the New England Journal of Medicine (NEJM), finds at up to 10 years, when...
Hence then, the article about new data from the danger shock randomized control trial published in the new england journal of medicine confirms the long term survival benefit of the impella cp heart pump was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump )
Also on site :
- U.S. government is spending $88 billion a month in interest on national debt—equal to spending on defense and education combined
- Goldfish Is Offering Fans Free Crackers for Tax Day—Here’s How To Claim Yours
- John Travolta Gushes Over Daughter Ella Bleu As She Flaunts Strong Family Genes in Rare Red Carpet Photos